Search clinical trials for: LEO 43204 gel 0.1%

Total 288 results

LEO Pharma

Completed

Pharmacokinetics of LEO 43204 Gel in Actinic Keratosis Administered Under Maximal Use Conditions

Actinic Keratosis

United States
LEO Pharma

Completed

Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up

Actinic Keratosis

United States
LEO Pharma

Completed

Efficacy and Safety of LEO 43204 in the Field Treatment of Actinic Keratosis on Face or Chest including12-month Follow-up

Actinic Keratosis

United States
LEO Pharma

Completed

Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up

Actinic Keratosis

United States
LEO Pharma

Completed

Biological Effects of LEO 43204 in Actinic Keratosis

Actinic Keratosis

United States
LEO Pharma

Completed

A Clinical Study to Evaluate the Sensitizing Potential of LEO 43204 Gel

Actinic Keratosis

United States
LEO Pharma

Terminated

A Trial to Compare the Incidence of Squamous Cell Carcinoma (SCC) and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp

Actinic Keratosis | Squamous Cell Carcinoma

United States, Spain, Canada, Germany, France, United Kingdom
LEO Pharma

Completed

A Study of Increasing Strengths, Safety and Efficacy of Two Formulas of LEO 43204 on the Face or the Chest in Patients With Actinic Keratosis

Actinic Keratosis

Canada, United States
LEO Pharma

Completed

Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis

Actinic Keratosis

United States, Canada
LEO Pharma

Completed

Safety of LEO 43204 for Actinic Keratosis Applied on Face/Chest, Scalp and Trunk/Extremities, Respectively

Actinic Keratosis

United States
LEO Pharma

Completed

Safety and Efficacy of Doses of LEO 43204 Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis

Actinic Keratosis

United States
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.

Recruiting

A First-in-Human Study of QY211 Gel in Adult Subjects

Atopic Dermatitis

China
Eisai Limited

Completed

A 12-Day Randomized, Blinded, Vehicle and Active Comparator-Controlled Study to Determine the Efficacy and Safety of Six Concentrations of Topical E6201 Gel in Subjects With Psoriasis Vulgaris

Psoriasis Vulgaris

Germany
GlaxoSmithKline

Completed

Study to Investigate the Irritation Potential of GSK1940029 Gel

Acne Vulgaris

Australia
Galderma R&D

Completed

Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris

Acne Vulgaris

United States, Canada
Hoth Therapeutics, Inc.
Worldwide Clinical Trials

Recruiting

Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors (CLEER)

Acneiform Eruption Due to Chemical | Xerosis Cutis | Paronychia

United States
Shaperon

Completed

A Phase II Study of HY209 Gel for Atopic Dermatitis Patients (Shaperon)

Atopic Dermatitis

Korea, Republic of
Galderma R&D

Completed

A Pilot Study to Investigate Filiation Between Primary and Secondary Lesions in Acne Patients

Acne

Canada, France
LEO Pharma

Completed

Dermatopharmacokinetic Trial of LEO 80185 Gel

Psoriasis Vulgaris

Japan
TR Therapeutics

Completed

Efficacy Study of GLYC-101 to Evaluate Outcomes After Laser Ablation

Wounds

United States
GlaxoSmithKline

Completed

Study to Evaluate the Safety, Tolerability and Pharmacokinetic of Single and 14 Day Repeat Topical Application of GSK1940029

Acne Vulgaris

Australia
SerenaGroup, Inc.
TR Therapeutics

Unknown

Efficacy of TR 987, Beta-1,3-1,6-D-glucan, in the Treatment of Chronic Venous Insufficiency Ulcers

Venous Leg Ulcer

United States
Children's Hospital of Orange County

Completed

Comparison of 2 Application Techniques for LET Gel Used Prior to Simple Laceration Repair (LET)

LET | Laceration of Skin

United States
Galderma R&D

Completed

Differin® Gel x12 Wks vs Tazorac® Cream x12 Wks vs Differin® x6 Wks Switched to Tazorac® x6 Wks for Treatment of Acne

Acne Vulgaris

United States
DermBiont, Inc.

Active, not recruiting

A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Tinea Pedis

Tinea Pedis

United States
Universidade Federal do Para

Completed

Whitening Efficacy and Tooth Sensitivity of Different Concentrations of Hydrogen Peroxide Photoactivated With Violet or Blue LEDs

Color | Bleaching Sensitivity

Brazil
Fondazione Don Carlo Gnocchi Onlus

Completed

Efficacy of End-Effector Robot-Assisted Gait Training Combined With Robotic Balance Training in Subacute Stroke Patients

Stroke

Italy
Starpharma Pty Ltd

Completed

Dose Ranging Study of SPL7013 Gel for Treatment of Bacterial Vaginosis (BV)

Bacterial Vaginosis

United States
LEO Pharma

Completed

A Clinical Trial to Assess the Potential of LEO 130852A Gel to Reduce Steroid Induced Skin Atrophy on Healthy Skin

Connective Tissue Diseases | Skin Tissue Diseases

Germany
Galderma R&D

Withdrawn

Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Persistent Facial Erythema

Erythema
Nutravalia
Slb Pharma

Completed

Effect of ANACA3 Slimming Gel on Loss of Abdominal and Thigh Circumferences in Healthy Volunteers

Overweight and Obesity

France
Pfizer

Completed

RIPT of Ibuprofen Topical Gel

Pain

United States
DermBiont, Inc.
Derm Research, PLLC; Northsoundderm; ClearDermatologyandAestheticsCenter

Terminated

Study the Safety and Efficacy of DBI-001 Gel Versus Aqueous Gel

Atopic Dermatitis

United States
Galderma R&D

Completed

Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea

Rosacea

United States
Jinnah Postgraduate Medical Centre

Completed

Comparing the Efficacy of Topical Tazarotene Gel 0.1% v/s Microneedling in Atrophic Post Acne Scars

Acne Scar

Pakistan
Spear Pharmaceuticals

Completed

Bioequivalence Study of Generic Tretinoin 0.1% Microsphere Gel, 0.1% Retin-A Micro® and Placebo

Acne

United States
KGL, Inc.
NYU Langone Health; Milton S. Hershey Medical Center; Allergan; State University... and other collaborators

Completed

Comparison of Tazarotene and Minocycline Therapies for Maintenance of Facial Acne Vulgaris

Acne Vulgaris

United States
TWi Biotechnology, Inc.

Completed

Prophylactic Treatment of Skin Rash Associated With EGFR Inhibitor Therapy

EGFR Inhibitor-Induced Skin Rash

Taiwan
Peplin

Completed

Study to Determine the Sensitizing Potential of PEP005 Topical Gel in Healthy Volunteers Using a Repeat Insult Patch Test Design

Healthy

United States
BioPharmX, Inc.

Completed

BPX-01 Minocycline Topical Gel in the Treatment of Acne Vulgaris (OPAL)

Acne Vulgaris

United States
Insud Pharma
Allergan Sales, LLC

Completed

Safety and Tolerability of Metronidazole Gel 1.3%

Vaginosis, Bacterial

United States
Taro Pharmaceuticals USA

Completed

A Study Comparing Tretinoin Gel Microsphere, 0.1% and RETIN-A MICRO ® Gel Microsphere, 0.1% in the Treatment of Acne Vulgaris

Acne Vulgaris

United States
Horus Pharma

Unknown

Evaluation of Efficacy and Safety of Vismed Gel Multi 0.3% Versus Vismed Multi 0.18% on Treatment of Ocular Dryness

Dry Eye
NantBioScience, Inc.

Active, not recruiting

QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.

Melanoma | Breast Cancer | Colorectal Cancer | Pancreatic Cancer | Non Small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Liver Cancer

United States
LEO Pharma

Completed

LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris

Psoriasis Vulgaris

France
BioPharmX, Inc.

Completed

BPX-01 Minocycline 1% Topical Gel for Reduction of Propionibacterium Acnes

Acne Vulgaris

United States
LEO Pharma

Completed

Safety and Efficacy of LEO 80185 Topical Suspension in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis

Scalp Psoriasis

United States
GlaxoSmithKline

Completed

DUAC® Early Onset Efficacy Study in Japanese Subjects

Acne Vulgaris

Japan
DermBiont, Inc.

Suspended

A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Onychomycosis

Onychomycosis

United States
Allergan

Completed

Safety, Tolerability and Pharmacokinetics of AGN-190168 in Subjects With Acne Vulgaris

Acne Vulgaris

United States

3

Subscribe